Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion

• Published in: Molecular genetics & genomic medicine Vol. 3; no. 2; pp. 130 - 136
• Main Authors: Sekulic, Aleksandar, Liang, Winnie S., Tembe, Waibhav, Izatt, Tyler, Kruglyak, Semyon, Kiefer, Jeffrey A., Cuyugan, Lori, Zismann, Victoria, Legendre, Christophe, Pittelkow, Mark R., Gohmann, John J., De Castro, Fernando R., Trent, Jeffrey, Carpten, John, Craig, David W., McDaniel, Timothy K.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.03.2015; BlackWell Publishing Ltd
• Subjects: CD28; CTLA4; Original; Sézary syndrome; CD28; Sézary syndrome; CTLA4
• ISSN: 2324-9269; 2324-9269
• DOI: 10.1002/mgg3.121

Matching molecularly targeted therapies with cancer subtype‐specific gene mutations is revolutionizing oncology care. However, for rare cancers this approach is problematic due to the often poor understanding of the disease's natural history and phenotypic heterogeneity, making treatment of these cancers a particularly unmet medical need in clinical oncology. Advanced Sézary syndrome (SS), an aggressive, exceedingly rare variant of cutaneous T‐cell lymphoma (CTCL) is a prototypical example of a rare cancer. Through whole genome and RNA sequencing (RNA‐seq) of a SS patient's tumor we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipilimumab resulted in a rapid clinical response. Our findings suggest a novel driver mechanism for SS, and cancer in general, and exemplify an emerging model of cancer treatment using exploratory genomic analysis to identify a personally targeted treatment option when conventional therapies are exhausted. Using whole genome and RNA sequencing on a Sezary syndrome patient's tumor, we discovered a highly expressed gene fusion between CTLA4 (cytotoxic T lymphocyte antigen 4) and CD28 (cluster of differentiation 28), predicting a novel stimulatory molecule on the surface of tumor T cells. Treatment with the CTLA4 inhibitor ipilimumab resulted in a rapid clinical response.